Health News

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs, décolletage, and upper arms. Sculptra can be used across these areas to address varied treatment goals – from impr...

BRISBANE, Australia--(BUSINESS WIRE)--Dial A Vet, Australia’s fastest-growing veterinary telehealth platform, has announced a national partnership with Pawssum Mobile Vets, Australia’s largest Mobile vet service, to launch the country’s first fully integrated online-to-in-home veterinary care pathway. This collaboration bridges the gap between digital advice and physical treatment, offering Australian pet owners a seamless veterinary experience. Through this alliance, owners receive immediate o...

PRINCETON, N.J.--(BUSINESS WIRE)--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollm...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollm...

IRVINE, Calif.--(BUSINESS WIRE)--Nihon Kohden, a global leader in neurodiagnostic technology, will showcase its integrated EEG portfolio at the American Epilepsy Society (AES) 2025 Annual Meeting, held December 5–9 in Atlanta. Attendees are invited to Booth #725 to explore solutions shaped through extensive collaboration with the clinicians who use them—bringing together mobility, connectivity and performance to advance neurological care. With a history of advancing EEG technology that predates...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year...

WASHINGTON--(BUSINESS WIRE)--The Public Access to Sunscreens (PASS) Coalition commends Congress for passing the SAFE Sunscreen Standards Act (H.R. 3686/S. 2491) as part of the recent reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA) in H.R. 5371. This action represents a pivotal step toward modernizing sunscreen ingredient approvals and expanding access to safe and innovative cancer prevention tools. For years, outdated regulatory frameworks have restricted Americans’ acces...

NORTHBROOK, Ill.--(BUSINESS WIRE)--IDEX Corporation announces Sean M. Gillen as Senior Vice President and Chief Financial Officer, effective January 5, 2026....

TORONTO--(BUSINESS WIRE)--dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL) is pleased to announce that, at the special meeting of the Company’s securityholders (the "Securityholders”) held on December 4, 2025, Securityholders approved the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement whereby a newly formed acquisition vehicle controlled by GTCR LLC (“GTCR”) will acquire all of Dentalcorp’s issued and outstanding subo...